<DOC>
	<DOCNO>NCT00427440</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety AMG 102 treatment Advanced Malignant Glioma .</brief_summary>
	<brief_title>A Phase II Study Treat Advanced Malignant Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Dihydrotachysterol</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>subject document histologically confirm primary grade 4 advance malignant glioma 3 prior relapse prior systemic treatment recurrent disease document MRI prior therapy must least one site bidimensionally measurable disease : archive tissue initial diagnosis advance malignant glioma upon transformation advance malignant glioma available central review within approximately 4 week enrollment age ≥ 18 year Karnofsky performance score ≥ 60 % hemoglobin ≥ 10 g/dL absolute neutrophil count ≥ 1.5 x 10 ( 9th ) /L platelet count ≥ 100 x 10 ( 9th ) /L serum creatinine ≤ 1.5 time upper limit normal alanine aminotransferase ≤ 2.5 time upper limit normal serum total bilirubin ≤ 2.5 time upper limit normal studyspecific procedure , appropriate write informed consent must obtain history central nervous system bleed define stroke intraocular bleed ( include embolic stroke ) within 6 month enrollment evidence acute intracranial/intratumoral hemorrhage ; except subject stable grade 1 hemorrhage receive radiation therapy within 4 week enrollment recover toxic effect therapy treat previously cMet HGF target therapy treat thalidomide tamoxifen within 1 week enrollment recover toxic effect cancer therapy treat immunotherapeutic agent , vaccine mAb therapy within 4 week enrollment recover toxic effect cancer therapy treat alkylating agent within 4 week enrollment recover toxic effect cancer therapy treat chemotherapy ( nonalkylating agent ) within 2 week enrollment recover toxic effect cancer therapy surgical resection brain tumor within 4 week enrollment recover acute side effect therapy , except neurological effect plan receive surgery , radiation therapy elective surgery course study concurrent severe and/or uncontrolled medical disease ( e.g. , uncontrolled diabetes , congestive cardiac failure , myocardial infarction within 6 month enrollment ) could compromise participation study active infection within 7 day enrollment past current history another neoplasm , except curatively treat nonmelanoma skin cancer , carcinoma situ cervix primary solid cancer know active disease present curative adjuvant treatment administer last 3 year document history human immunodeficiency virus document history chronic viral hepatitis concurrent prior ( within 7 day enrollment ) anticoagulation therapy , except : Use low molecular weight heparin ( LMWH , e.g. , enoxaparin sodium [ Lovenox ] unfractionated heparin prophylaxis central venous catheter thrombosis allow Use low dose warfarin ( &lt; 2 mg/day ) prophylaxis central venous catheter thrombosis allow currently enrol yet complete least 30 day since end investigational device therapeutic study ( ) major surgery within 4 week enrollment recover prior surgery know allergy sensitivity excipients investigational product pregnant breast feed unwilling use adequate contraceptive precaution course study 6 month last administration investigational product , : male subject female subject postmenopausal ( menstrual period minimum 12 month study entry ) document surgically sterile bound exclusion previously treat AMG 102 previously enrol study available followup assessment disorder compromise ability subject give write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Glioma</keyword>
	<keyword>Brain Tumor</keyword>
</DOC>